ORLANDO — Genetic testing is warranted in patients with epilepsy of unknown origin, new research suggests. Investigators found that pathogenic genetic variants were identified in over 40% of patients ...

STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...

Most newly diagnosed patients with epilepsy do gain lasting control of their seizures, even if their first medication doesn’t ...

Please provide your email address to receive an email when new articles are posted on . The study included 250 patients with epilepsy. A history of delayed development and earlier seizure onset were ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...

Noninvasive tests performed in midlife may help identify people who are at risk of late-onset epilepsy (LOE), a new study suggests. New data from the Framingham Heart Study show those who scored ...

The University of Utah College of Pharmacy's Anticonvulsant Drug Development (ADD) Program has been awarded a five-year $19.5 million contract renewal with the National Institutes of Health (NIH) to ...

N ovember is National Epilepsy Awareness Month, and one Anthony Wayne High School senior is proving that life with epilepsy ...

The Patient Access Program helps to ensure more equitable care across pediatric epilepsy populations. Exome testing is recommended as a first-line test for patients with unexplained epilepsy by the ...